FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, particularly to an anti-CD3 antibody or an antigen-binding fragment of an antibody. Also disclosed is a nucleic acid coding said antibody, an expression vector, a host cell for expressing said antibody, a pharmaceutical composition containing said antibody. Disclosed is a method of treating the disorder in a mammal using said antibody.
EFFECT: invention makes it possible to effectively treat disorders in a mammal using said antibody.
59 cl, 6 dwg, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| BINDING DOMAINS OF ANTI-CD3 ANTIBODIES AND ANTIBODIES CONTAINING THEM, AS WELL AS METHODS OF THEIR PREPARATION AND APPLICATION | 2018 |
|
RU2807040C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
| CD33, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2820603C2 |
| HETERODIMERIC FC-FUSED PROTEINS IL15/IL15Rα | 2017 |
|
RU2779938C2 |
